Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing

Mrinal M Patnaik, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Rebecca King, Rhett P. Ketterling, Naseema Gangat, Ayalew Tefferi

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) shares overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). RARS-T is characterized by SF3B1 and JAK2 mutations and prognosis is considered to be better than MDS but not as good as MPN. The objective of the study was to identify predictors of survival in RARS-T. We analyzed clinical and laboratory variables in 82 patients and applied a 27-gene NGS assay to 48 marrow samples obtained at diagnosis. 94% of patients had ≥1 mutations; common mutations being: SF3B1 85%, JAK2V617F 33%, ASXL1 29%, DNMT3A 13%, SETBP1 13% and TET2 10%. In a multivariable survival analysis (n=82), anemia (P=0.02) [HB<10 gm/dl: HR 2.3, 95% CI 1.2-4.6] and abnormal karyotype (P =01) [HR 6.1, 95% CI 2.7-13.8] were independently prognostic for inferior survival. In patients with NGS information (n=48), univariate analysis showed association between poor survival and presence of SETBP1 (P=0.04) or ASXL1 (P=0.08) mutations whereas the absence of these mutations (ASXL1wt/SETBP1wt) was favorable (P=0.04); the number of concurrent mutations did not provide additional prognostication (P=0.3). We developed a HR-weighted, with 2 points for an abnormal karyotype, 1 point for either ASXL1 and/or SETBP1 mutations, and 1 point for a HB level

Original languageEnglish (US)
Pages (from-to)492-498
Number of pages7
JournalAmerican Journal of Hematology
Volume91
Issue number5
DOIs
StatePublished - May 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this